PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.89%
Both companies show declining cash positions (-7.89% vs AVXL's -13.73%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.89%
Cash + STI yoy 0.5-0.75x AVXL's -13.73%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.62%
0.5-0.75x AVXL's -13.61%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-4.83%
Below half AVXL's -24.73%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.38%
Below half of AVXL's -24.73%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
0.5-0.75x AVXL's -13.61%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
-25.56%
Above 1.5x AVXL's -2.65%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-49.71%
Less than half of AVXL's 6.96%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
240.62%
Below half of AVXL's -83.28%. Michael Burry suspects a big gap in pre-sales traction.
-18.75%
Less than half of AVXL's -83.28%. David Dodd sees fewer expansions in other current obligations.
-24.27%
Above 1.5x AVXL's -3.98%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.27%
Above 1.5x AVXL's -3.97%. Michael Burry sees a potential leverage warning sign.
5.27%
Above 1.5x AVXL's 3.01%. Michael Burry suspects heavy new equity expansion or dilution.
-5.68%
≥ 1.5x AVXL's -3.02%. David Dodd sees higher yoy retained profits than competitor.
-17.53%
Less than half of AVXL's 100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Below half AVXL's -15.73%. Michael Burry sees potential underperformance in building shareholder capital.
-7.59%
0.5-0.75x AVXL's -13.61%. Martin Whitman sees underexpansion or possible missed opportunities.
No Data
No Data available this quarter, please select a different quarter.
-49.71%
Less than half of AVXL's 7.02%. David Dodd sees less overall debt expansion vs. competitor.
7.55%
50-75% of AVXL's 13.86%. Bruce Berkowitz notes comparatively lower net debt expansion.